Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrexafungerp for Complicated VVC Failed by Fluconazole
NCT05399641Phase 3Completed
- Sponsor
- SCYNEXIS, Inc.
- Start
- May 2022
- Primary completion
- May 2023
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
A Phase 3 trial of ibrexafungerp in vulvovaginal candidiasis (VVC), sponsored by SCYNEXIS, Inc.. Started May 2022; status: completed.
02
Drugs
ibrexafungerp
03
Conditions
vulvovaginal candidiasis (VVC)
Beyond the preview
Go deeper on NCT05399641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05399641.